IPSEN (OTCMKTS:IPSEY - Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $32.42 and last traded at $32.42, with a volume of 1582 shares trading hands. The stock had previously closed at $30.79.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of IPSEN in a research report on Wednesday, April 2nd.
View Our Latest Stock Analysis on IPSEN
IPSEN Trading Down 1.8%
The firm's 50-day moving average is $30.05 and its 200 day moving average is $29.57.
IPSEN Increases Dividend
The firm also recently announced a dividend, which was paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th were given a dividend of $0.2896 per share. The ex-dividend date was Monday, June 9th. This is an increase from IPSEN's previous dividend of $0.23. This represents a dividend yield of 0.97%.
About IPSEN
(
Get Free Report)
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
See Also
Before you consider IPSEN, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IPSEN wasn't on the list.
While IPSEN currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access